- A gross income of $250,000 or more per annum in each of the previous two financial years; or
- Net assets of at least $2.5 million; and
- A verified Qualified Accountant’s certificate given no more than two (2) years ago confirming the Sophisticated Investor status. Please refer to the Corporations Act: Specifically Section 708(08) and Section s761G(7)
Prescient Therapeutics Reports Strong Progress in PTX-100 Phase 2a Study and New CMO Appointment
Prescient Therapeutics Limited has reported significant advancements in its clinical trial for PTX-100, with patient...
Why Prescient Therapeutics (ASX:PTX) Tops Biotech Penny Watchlists
Prescient Therapeutics anchors biotech penny watchlists as its OmniCAR cell therapy platform draws steady attention,...
Prescient Therapeutics Within All Ordinaries Biotechnology Landscape
Prescient Therapeutics advanced clinical biotechnology activity through European regulatory authorisations while maintaining participation within the...
Prescient Therapeutics Advances PTX-100 to Phase 2 in Fight Against T-Cell Lymphoma
Highlights,PTX-100 enters Phase 2 trial for relapsed and refractory Cutaneous T-Cell Lymphoma, Analysts lift valuation...
Prescient Therapeutics (ASX: PTX) Launches SPP to Boost Cancer Therapy Trials | All Ordinaries
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.
Prescient Therapeutics Leads ASX200 Biotech Push With Innovations in Cancer Therapy (ASX:PTX)
PTX-100 targets high-mortality cancers linked to RAS mutations.
Prescient’s PTX-100 Enters Phase 2A Trial for Rare Lymphoma, Boosting ASX200 Biotech Momentum
Prescient Therapeutics (ASX: PTX) begins Phase 2A trial of PTX-100 for rare lymphoma, drug shows...
Prescient Therapeutics opens first clinical site for Phase 2a PTX-100 trial in cutaneous T-cell lymphoma
Prescient Therapeutics Ltd (ASX: PTX) initiates a Phase 2a clinical trial for PTX-100 in cutaneous...
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a...
